Sarepta Therapeutics, Inc. Class Action Notice: Robbins LLP Reminds SRPT Stockholders of the Lead Plaintiff Deadline in the SRPT Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Allegations and Safety Concerns - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during trial protocols [2]. - It is alleged that the severity of adverse events from ELEVIDYS treatment led to the halting of recruitment and dosing in clinical trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [2]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 25, 2025, with the option to remain an absent class member if they choose not to take action [5].